

インタビュー翻訳

Dr. Louis B. Jacques インタビュー： CMSの方針とPETイメージング

— 保険適用に関する科学的エビデンスと倫理的意味 —*1

Louis B. Jacques*2

Senior Vice President & Chief Clinical Officer, ADVI Reimbursement & Health Policy Consultancy

インタビュー・訳 栗原千絵子*3

放射線医学総合研究所分子イメージング研究センター
(2014年6月13日金 於：ADVI, ワシントンD.C., アメリカ)

Interview with Dr. Louis B. Jacques on insurance coverage policy of CMS focusing PET imaging

— Scientific evidence and social, ethical implications
concerning healthcare reimbursement —

Interview and translation: Chieko Kurihara

Molecular Imaging Center, National Institute of Radiological Sciences (NIRS)

(June 13, 2014, ADVI, Washington D.C., United States)

Abstract

This is the record of an interview with Dr. Louis Jacques, M.D., Senior Vice President & Chief Clinical Officer, ADVI Reimbursement & Health Policy Consultancy, on June 13, 2014, at his office in Washington D.C., United States. He had just left CMS (Centers for Medicare & Medicaid Services) at the end of February 2014 after 11 years of contribution. He is a key-person to whom the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Alzheimer's Association presented arguments seeking a positive decision of the CMS on Medicare coverage of beta-amyloid imaging PET (Positron Emission Tomography) scan for finding cognitive disease. He was a responsible person, as the Director, Coverage and Analysis Group, Center for Clinical Standards and Quality, at the time of final decision memo of the CMS which allowed only a 1-time scan of amyloid imaging to be covered in the CMS-approved studies under the scheme of CED (Coverage with Evidence Development).

He also talked about the profound idea of the scientific, social, and ethical implication of the diagnosis of Alzheimer's disease, as well as a rationally designed framework of the CED. We Japanese can learn much from this talk to consider future perspectives of the design of health insurance coverage of advanced medical technologies to conquer many of our incurable diseases.

Key words

CMS (Centers for Medicare & Medicaid Services), PET (Positron Emission Tomography), amyloid-beta, CED (Coverage with Evidence Development), NOPR (National Oncologic PET Registry)

Rinsho Hyoka (Clinical Evaluation). 2015 ; 43 : 235-46.

*1 本インタビュー記事は、本誌ホームページに掲載された英語版 (http://homepage3.nifty.com/cont/43_1/w73-w84eng.pdf) の翻訳である。

*2 前Director, Coverage and Analysis Group, Center for Clinical Standards and Quality, Centers for Medical & Medicaid services

*3 放射線医学総合研究所放射線防護研究センター；同研究倫理企画支援室；「臨床評価」編集スタッフ (Research Center for Radiation Protection; Research Governance and Human Research Protection Office, NIRS ; Editorial Staff, *Rinsho Hyoka (Clinical Evaluation)*)